Alfresa Holdings Corporation
13.55
USD
-0.25
(-1.81%)
ISIN
US0155091020
CUSIP
015509102
Return %
Stock
S&P 500
1Y
-15.26
14.20
3Y
0.97
81.12
5Y
-41.97
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Ryuji Arakawa
- Full Time Employees
- 12,525
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Ote Center Building Tokyo TY Japan 100-0004
- IPO Date
- Sep 29, 2003
- Website
- alfresa.com
- Similar Companies
- Business
- Alfresa Holdings Corporation Alfresa Holdings Corporation (2784.T), founded on September 29, 2003 and headquartered at 1-1-3 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan, manages subsidiaries engaged in the wholesaling, manufacturing, marketing, import/export of pharmaceuticals, diagnostic reagents, medical devices and equipment; it operates primarily in Japan with international activities. The company conducts business across four main segments: ethical pharmaceuticals wholesaling, which supplies prescription drugs, diagnostic reagents, medical devices, equipment and materials to hospitals, clinics and dispensing pharmacies; self-medication products wholesaling, offering over-the-counter drugs, health foods and supplements to drug stores and pharmacies; manufacturing, producing active pharmaceutical ingredients, finished pharmaceuticals, diagnostic reagents and medical devices including contract manufacturing services; and medical-related services, encompassing dispensing pharmacies and other healthcare support operations. In recent developments, Alfresa Holdings entered a capital and business alliance with GEXVal Inc. in March 2025 to develop high-quality drugs for rare diseases and underserved medical conditions; formed a business alliance with Minaris Regenerative Medicine Co., Ltd. in March 2025 to advance cell therapies and regenerative medicine through complementary manufacturing, procurement and distribution capabilities; signed a strategic partnership with HekaBio K.K. in June 2025, including capital investment, to accelerate commercialization of innovative therapies in CNS, oncology and regenerative medicine via Alfresa's total supply chain services in Japan and Asia-Pacific. Further, in January 2025, Alfresa Corporation, a key subsidiary, agreed to a business and capital alliance with Medley, Inc. involving share exchange to enhance digital transformation solutions for pharmacies, hospitals and clinics including electronic medication records; TS Alfresa Corporation acquired shares in Miyanomedix Inc. in September 2025 to bolster medical devices trading; established a basic business cooperation with K Pharma, Inc. in November 2025 for iPS cell-derived regenerative medicine supply chain, including investment in new bonds with warrants; and in September 2025, reached a basic agreement with Ai Ken Pharma Asia Pacific Holdings Pte. Ltd. for joint business development in Southeast Asia, focusing on full-agency pharmaceutical operations and sales channels for Japanese firms.
Company News
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight